January 18, 2013

China's IBD poultry vaccine surpasses standards, challenges foreign monopoly

Five Chinese biotech companies paid RMB 15.6 million (US$2.51 million) for two patented poultry vaccine technology developed in the Henan Agricultural University, signaling the end of foreign monopoly in China's animal vaccine sector.

The success of this vaccine not only breaks the monopoly of foreign companies in this area, but also exceeded the current technical level, being four to eight times more effective than similar vaccines.

In the poultry industry, the infectious bursal disease in chicks is an acute, contagious disease. It is often endemic, hence a devastating blow to poultry producers. Due to technical bottlenecks in China, the local industry imports 95% of the required vaccines.

This vaccines is also known to reduce flocks stress, reduce the bursa of the vaccine virus and wild toxic pollution in the environment, reduce immune suppression, improve flocks immune performance, therefore expected to gradually control and eradicate infectious bursal disease, resulting in huge economic and social benefits.